AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Genzyme Molecular Oncology Patents Newly Discovered Immunogens.(Brief Article)
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- Genzyme Molecular Oncology (GZMO) has been issued a U.S. patent for the discovery of novel synthetic peptides and pharmaceutical compositions useful as therapeutic melanoma vaccines.
Discovered by Genzyme's antigen discovery group led by Charles A. Nicolette, PhD, the peptide ligands are superior immunogens when compared with the native gp100 epitope. The newly issued melanoma antigen patent provides synthetic peptide ligand variants of the 209 T-cell epitope of gp100 that may be useful in developing potent melanoma vaccines.
"Issuance of this patent is a key milestone for Genzyme Molecular Oncology," said Gail Maderis, president of Genzyme Molecular Oncology. "It is our first patent to issue on SPHERE peptides and demonstrates the ability of our SPHERE technology to identify novel, patentably distinct molecules, even in widely studied genes such as gp100. Furthermore, it comes at a fitting time as we prepare to initiate our first SPHERE peptide clinical trial in melanoma next year."
Genzyme ...
- Genzyme Molecular Oncology Stock Begins Trading Today.
- Press release article from: PR Newswire November 16, 1998 700+ words
...Corp. announced that Genzyme Molecular Oncology common stock begins trading...outstanding. In addition, Genzyme Molecular Oncology shares will be distributed...is 0.10805 share of Genzyme Molecular Oncology common stock for each...
- Genzyme Molecular Oncology Achieves Milestones Totaling $3 Million in January...
- Press release article from: PR Newswire February 7, 2000 700+ words
...7 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO) today...trials. In October 1998, Genzyme Molecular Oncology licensed its rights to...terms of this agreement, Genzyme Molecular Oncology has the potential to...
- Genzyme Molecular Oncology Announces Call For Abstracts to SAGE 2003 Conference...
- Press release article from: PR Newswire October 7, 2002 700+ words
...Understanding of Human Genome Genzyme Molecular Oncology announced today that...Maderis, president of Genzyme Molecular Oncology. "This has been a very...2003 is sponsored by Genzyme Molecular Oncology, Invitrogen, and the...
- Genzyme Molecular Oncology Expands Antiangiogenesis Focus With Appointment of...
- Press release article from: PR Newswire January 14, 2002 700+ words
...FRAMINGHAM, Mass. -- Genzyme Molecular Oncology today announced further...responsibility for directing Genzyme Molecular Oncology's research efforts...lead the project for Genzyme Molecular Oncology, and also design and...
- Genzyme Molecular Oncology Receives U.S. Patent Covering LongSAGE(TM).
- Press release article from: PR Newswire January 27, 2003 700+ words
Genzyme Molecular Oncology today announced that the United...Gail Maderis, president of Genzyme Molecular Oncology. "We are now performing...LongSAGE method is utilized by Genzyme Molecular Oncology in both its antigen discovery...
- Genzyme Molecular Oncology's SAGE (TM) Genomics Technology Utilized to Discover...
- Press release article from: PR Newswire August 17, 2000 700+ words
...17 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO) today...Hopkins University, Genzyme Molecular Oncology has rights to all intellectual...Maderis, president of Genzyme Molecular Oncology. "The results of this...
- Genzyme Molecular Oncology Receives Patent Covering Novel Peptide Corresponding...
- Press release article from: PR Newswire March 18, 2003 700+ words
Genzyme Molecular Oncology today announced that the U...director of antigen discovery for Genzyme Molecular Oncology, using the patented SPHERE...Gail Maderis, president of Genzyme Molecular Oncology. "The clinical utility of...
- Genzyme Molecular Oncology Establishes Marketing Agreement with Celera Genomics.
- Press release article from: PR Newswire September 25, 2000 700+ words
...25 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO) today...Under the agreement, Genzyme Molecular Oncology will license its SAGE...revenue sharing basis. Genzyme Molecular Oncology will provide Celera with...